tapebrief
VRTX · Q4 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VRTX · Q1 2026 Earnings

Vertex Pharmaceuticals

Reported May 4, 2026

30-second summary

Q1 FY2026 revenue of $2.99B grew 8% YoY — a modest one-point beat versus the ~7% YoY Q1 guide telegraphed on the Q4 FY2025 call — with non-GAAP EPS of $4.47, GAAP EPS of $4.02, and non-GAAP operating margin of 43.8%. FY2026 revenue guidance was reaffirmed at $12.95–13.1B, the $500M+ non-CF floor was reaffirmed, and the combined non-GAAP opex range of $5.65–5.75B was held — but the substantive news is operational: POVI IgAN BLA submitted in 27 days (fastest in Vertex history) on "sparkling" Phase 3 interim data, VX522 CF mRNA program discontinued for tolerability, and management now framing renal as a franchise that "can rival, if not crest, CF."

Headline numbers

EPS

Q1 FY2026

$4.47

Revenue

Q1 FY2026

$2.99B

+8.0% YoY

Gross margin

Q1 FY2026

86.9%

Operating margin

Q1 FY2026

38.1%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$2.99B+8.0%$3.19B-6.3%
EPS$4.47—$5.03-11.1%
Gross margin86.9%—85.4%+150bps
Operating margin38.1%—37.8%+30bps

Guidance

Vertex reaffirmed its full-year 2026 revenue and operating expense guidance and beat Q1 2026 revenue growth by 1 percentage point.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ1 FY2026approximately 7% YoY$2.99B (8% YoY growth)+1pt above guideBeat

Reaffirmed unchanged this quarter: Revenue ($12.95B to $13.1B), Non-CF product revenue ($500 million or more), Combined non-GAAP R&D, AIPR&D and SG&A expenses ($5.65 to $5.75 billion), Combined GAAP R&D, AIPR&D and SG&A expenses ($6.3 to $6.45 billion), Non-GAAP effective tax rate (19.5% to 20.5%)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
TRIKAFTA/KAFTRIO$2.355B-7.1%
ALYFTREK$0.424B+687.8%
Other CF products$0.136B-12.5%
CASGEVY$0.043B+202.1%
JOURNAVX$0.029B+2130.8%

Other KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
U.S. Revenue$1.78B+7.0%
International Revenue$1.21B+9.0%
CF Patient Population Coverage~95% of CF patients in core markets—
CASGEVY Eligible Patient Population>60,000 eligible patients (SCD/TDT)—
JOURNAVX Prescriptions Filled (Cumulative)>1 million since launch—
JOURNAVX Q1 2026 Prescriptions>350,000—
JOURNAVX Reimbursed Lives Covered~240 million individuals—
Non-GAAP Operating Margin43.8%—
Non-GAAP Net Income$1,147.0 million—
Cash, Cash Equivalents and Marketable Securities$13.0 billion—

Management tone

Q2 FY2025 strategic discipline → Q3 FY2025 capacity expansion → Q4 FY2025 franchise reframing (renal "will rival CF scale") → Q1 FY2026 renal franchise confirmed as fourth pillar with filed asset and discontinued legacy bet (VX522)

Renal has gone from "will rival CF" to a filed asset with a launch team being built. Three quarters ago renal was a single Phase 3 program. Two quarters ago a second pivotal (membranous nephropathy) was initiated before the lead read. One quarter ago management was openly comparing renal scale to CF. This quarter, management said: "We believe this is another vertical that can rival, if not crest, CF" and "We are very excited to begin building our fourth commercial pillar and creating another multi-billion dollar franchise at Vertex." The escalation from "will rival" to "can crest" CF is the most aggressive forward language Vertex has used about any non-CF franchise — paired with a filed BLA in IgAN, this is no longer aspirational positioning.

POVI has moved from Phase 3 candidate to filed asset in a single quarter. Last quarter the BLA was contingent on supportive interim data and committed to 1H FY2026. This quarter the interim came in with management calling the efficacy and safety "sparkling" — a word repeated multiple times, unusual for biotech management — and the BLA was filed 27 days from database lock, "the fastest submission in Vertex history." The CEO's framing of proteinuria as the proximal marker for the hard endpoint of death/dialysis/transplant is a clinical-conviction signal that goes beyond regulatory positioning into outcomes claims.

VX522 was discontinued, ending the next-gen CF mRNA bet. This is the cleanest negative tone shift of the call. Last quarter VX522 was framed as active development with the restart endorsed by the DSMC; this quarter management said "despite actions we have taken in the trial to overcome these issues, we have not been able to do so, and as such, we have chosen to discontinue the program." The implication for the long-term CF defense story — addressing the ~5% of patients without CFTR modulator responsiveness — is that delivery technology remains the unsolved problem and the runway for organic CF growth is more bounded than the prior pipeline diagram suggested.

CF label expansion has shifted the patient denominator without changing the ceiling. Management disclosed that label updates now extend Kaftrio/Alyftrek to "about 95% of people with CF, including those with rare and even N of 1 genotypes" — broadening coverage but inside an already-largely-penetrated population. The accompanying "if it is possible to do better in CF, we're committed to being the ones who do so" is a softer commitment than prior CF dominance language — it concedes the ceiling exists.

JOURNAVX has been reframed from launch volume story to gross-to-net normalization story. Management committed to "triple prescriptions for Genavix in 2026" and to "taper our patient support program over the course of 2026 and enter 2027 with a normalized gross-to-net." The 2027 normalization timeline is the most concrete PSP wind-down disclosure to date — but it also confirms that meaningful JOURNAVX revenue contribution to the $500M+ non-CF floor depends on PSP tapering through 2026, not stepping down cleanly.

Recurring themes management leaned on this quarter:

Renal franchise establishment as multi-billion dollar pillarCF label expansion driving incremental patient accessCommercial execution and revenue diversification across disease areasRapid regulatory submissions and clinical trial executionSafety and tolerability advantage as competitive differentiatorGross-to-net normalization and reimbursement breadth

Risks management surfaced:

VX522 lung inflammation from LNP delivery technologyDelivery technology challenges for non-CFTR producing CF patientsPotential foreign exchange headwindsTariff impact evaluation ongoingImmunosuppression and infection risks from B-cell modulating therapies

Answers to last quarter's watch list

Q1 FY2026 actual revenue vs. ~7% YoY guide — Q1 printed $2.99B at +8% YoY, a 1pt beat versus the ~7% guide. The beat is modest but directional: it removes the immediate Q1-miss tail risk on the FY 8–9% guide and management held FY guidance steady rather than raising the low end. The back-half acceleration story still needs to deliver — Q1 beat doesn't validate it, just doesn't undermine it. Status: Resolved positively
Journavx net revenue per Rx normalization — Q1 JOURNAVX revenue of $29M on >350,000 prescriptions implies roughly $83 per Rx. Management committed to PSP taper across FY2026 and "normalized gross-to-net" entering 2027 — the first concrete timeline — but the Q1 datapoint shows GTN remains the binding constraint and the $500M+ non-CF floor relies heavily on H2 PSP step-down. Status: Continue monitoring
Casgevy quarterly infusion pace — CASGEVY revenue of $43M with management flagging expected quarter-to-quarter variability as patients choose infusion timing. Management reiterated "very strong visibility" to a meaningful FY contribution and a back-half ramp from the built-out ATC network. Status: Continue monitoring
POVI Phase 3 IgAN interim analysis readout — Interim data was characterized as "sparkling" on efficacy and safety, and the BLA was filed 27 days from database lock — the fastest in Vertex history. Both timing and quality cleared. The launch readiness work is now the binding path. Status: Resolved positively
Trikafta/Kaftrio YoY trajectory — Trikafta/Kaftrio printed −7.1% YoY, but combined Trikafta+Alyftrek grew +7.3% YoY and total CF franchise +6% YoY per management — Alyftrek conversion is offsetting Trikafta erosion at the franchise level. Status: Resolved positively
POVI myasthenia gravis Phase 2 initiation timing — Phase 2 proof-of-concept study is underway: a 30-patient study evaluating 80mg and 240mg doses for 12 weeks with primary endpoints of safety and percent change from baseline in IgG at week 12. Status: Resolved positively

What to watch into next quarter

Q2 FY2026 revenue against the FY 8–9% YoY trajectory — Q1 printed +8% YoY; using the Q2 FY2025 base of $2.96B, the FY midpoint implies Q2 FY2026 revenue near $3.22B. A Q2 print below $3.20B would mean FY2026 is structurally dependent on H2 acceleration from JOURNAVX GTN improvement and POVI launch

JOURNAVX net revenue per Rx — Q1 implied ~$83 per Rx; watch whether Q2 net per Rx steps toward $100+ as PSP begins tapering, since the $500M+ non-CF floor requires meaningful GTN reset by H2

CASGEVY infusion pace — Q1 revenue of $43M against management's framing of quarter-to-quarter variability and a back-half-weighted ramp; watch whether Q2 demonstrates the sequential build management expects from the ATC network

POVI IgAN BLA acceptance and PDUFA date — BLA filed in 27 days; watch for FDA acceptance, the expedited six-month review clock starting, and PDUFA disclosure that anchor the timing of the renal launch

Trikafta/Kaftrio rate of decline — −7.1% YoY in Q1; watch whether decline stabilizes or accelerates as Alyftrek conversion matures — a Q2 print worse than −8% YoY would pressure the combined CF growth story even with Alyftrek offset

Combined non-CF revenue run-rate — Q1 non-CF (CASGEVY $43M + JOURNAVX $29M) = $72M, annualizing to ~$290M against the $500M+ FY floor; both contributors are explicitly back-half weighted per management (CASGEVY ATC infusion build, JOURNAVX PSP taper), so Q2 trajectory matters less than the H2 step-up — but watch Q2 for early evidence the ramp is on track

Sources

  1. Vertex Pharmaceuticals Q1 FY2026 press release (SEC EDGAR Ex-99.1): https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm
  2. Vertex Pharmaceuticals Q1 FY2026 earnings call transcript (prepared remarks and Q&A)
  3. Vertex Pharmaceuticals Q4 FY2025 press release and Tapebrief Q4 brief (prior quarter context, guidance baseline)
  4. Vertex Pharmaceuticals Q3 FY2025 and Q2 FY2025 Tapebrief briefs (cross-quarter tone context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.